Evidence map›Paper›PMID 29627935›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2018

Noradrenaline transporter availability on [

Franziska J Vettermann, Michael Rullmann, Georg A Becker, Julia Luthardt, Franziska Zientek, Marianne Patt, Philipp M Meyer, Anke McLeod, Matthias Brendel, Matthias Blüher and 5 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Franziska J VettermannIntegrated Research and Treatment Center (IFB) AdiposityDiseases, University Medical Center, Leipzig, Germany. Franziska.Vettermann@med.uni-muenchen.de.
Michael RullmannIntegrated Research and Treatment Center (IFB) AdiposityDiseases, University Medical Center, Leipzig, Germany.
Georg A BeckerDepartment of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
Julia LuthardtDepartment of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
Franziska ZientekIntegrated Research and Treatment Center (IFB) AdiposityDiseases, University Medical Center, Leipzig, Germany.
Marianne PattDepartment of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
Philipp M MeyerDepartment of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
Anke McLeodDepartment of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
Matthias BrendelDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Matthias BlüherDepartment of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany.
Michael StumvollIntegrated Research and Treatment Center (IFB) AdiposityDiseases, University Medical Center, Leipzig, Germany.
Anja HilbertIntegrated Research and Treatment Center (IFB) AdiposityDiseases, University Medical Center, Leipzig, Germany.
Yu-Shin DingDepartments of Radiology, Psychiatry and Chemistry , New York University School of Medicine Faculty, New York, NY, USA.
Osama SabriIntegrated Research and Treatment Center (IFB) AdiposityDiseases, University Medical Center, Leipzig, Germany.
Swen HesseIntegrated Research and Treatment Center (IFB) AdiposityDiseases, University Medical Center, Leipzig, Germany.
Leipzig University · DEIFB Adiposity Diseases · DELMU Klinikum · DELudwig-Maximilians-Universität München · DENew York University · US

Funding

IFB Adiposity Diseases, Federal Ministry of Education and Research (BMBF) FKZ: 01E01001
6 · The paper itself

Abstract

purposeAlthough the mechanisms by which the central noradrenaline (NA) system influences appetite and controls energy balance are quite well understood, its relationship to changes in body weight remains largely unknown. The main goal of this study was to further clarify whether the brain NA system is a stable trait or whether it can be altered by dietary intervention.

methodsWe aimed to compare central NA transporter (NAT) availability in ten obese, otherwise healthy individuals with a body mass index (BMI) of 42.4 ± 3.7 kg/m

resultsMRI-based individual volume-of-interest analyses revealed an increase in binding potential (BP

conclusionThese first longitudinal interventional data on NAT availability in highly obese individuals indicate that the central NA system is modifiable. Our findings suggest that NAT availability before intervention could help predict the amount and success of weight loss in obese individuals and help adjust treatment options individually by allowing prediction of the benefit of a dietary intervention.

Indexed as

Positron-Emission TomographyWeight LossAdultBody Mass IndexCarbon RadioisotopesFemaleGermanyHumansNorepinephrine Plasma Membrane Transport ProteinsObesityCarbon-11Carbon RadioisotopesNorepinephrine Plasma Membrane Transport ProteinsBMIMRINoradrenalineNoradrenaline transporterObesityPET

Identifiers

PMID29627935
OpenAlexW2796344447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.